V. V. Rubtsov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
V. V. Rubtsov has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Sergey V. Borisevich
48th Central Research Institute of the Ministry of Defense of the Russian Federation
8 shared publications - Sergey V. Savenko
48th Central Research Institute of the Ministry of Defense of the Russian Federation
6 shared publications - S. Ya. Loginova
48th Central Scientific Research Institute of the Ministry of Defense of the Russian Federation
5 shared publications - V. N. Shchukina
48th Central Scientific Research Institute of the Ministry of Defense of the Russian Federation
4 shared publications - D. A. Kutayev
FSBI «Central Scientific Research Institute No. 48» of the Ministry of Defense of the Russian Federation
3 shared publications - Victor T. Krotkov
48th Central Research Institute of the Ministry of Defense of the Russian Federation
3 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 25 (1) , 21-32
Preclinical valuation of immunogenicity and effectiveness of inactivated cultural vaccine experimental patterns against coronaviral infection COVID-19
Relevance. Research on the development of new, more advanced vaccines against Covid-19, both based on modern technologies and traditional inactivated ones, remains relevant. In the "48 Central Research Institute" of the Ministry of Defense of the Russian Federation, together with the Yaroslavl Factory of ready-made Dosage Forms of JSC R-Pharm, a cultural (based on Vero (B) cell culture) inactivated with beta-propiolactone chromatographically purified vaccine against coronavirus infection Covid-19 was developed. The aim of the work is to evaluate the results of preclinical studies on its immunogenicity and protective effectiveness in animal experiments. Materials and methods. The immunogenicity and protective activity of experimental vaccine samples with adjuvants aluminum hydroxide and CpG 1018 were evaluated, including in comparison with Sputnik V, after double immunization of Syrian hamsters with an interval of 21 days with intranasal infection with the virulent SARS-CoV-2 virus at a dose of 105 Plaqueforming units/individual. In an experiment on monkeys, the effects of the vaccine on double immunization were evaluated: humoral (virus neutralizing antibodies titer) and cellular immunity indicators for 1 year. Results and discussion. The optimal dose of the vaccine was selected – 15 mcg of protein and the composition of the adjuvants included in it was determined: 500 mcg of aluminum hydroxide and 10 mcg of synthetic oligodeoxynucleotide CpG 1018. The inactivated sorbed vaccine against Covid-19 coronavirus infection, when administered twice with an interval of 21 days, induces the formation of viral neutralizing antibodies in 80-100% of Syrian hamsters at titers of 1:20 or more 21 days after the completion of the immunization cycle and is characterized by a lung protection index ≥ 3.2 lg on the 6th day after infection with 105Plaque-forming units of virulent virus (variant “Delta”). The inactivated sorbed vaccine is capable of generating a humoral immune response in rhesus monkeys to both the “Delta” variant and the “Omicron” variant of the SARS-CoV-2 virus. Virus neutralizing antibodies for both variants persists in 100% of vaccinated animals for 180 days after double immunization. By 42 days after the completion of vaccination, there is an increase in cytotoxic T lymphocytes and a decrease in total B lymphocytes. Conclusions. The inactivated sorbed purified vaccine against Covid-19 coronavirus infection, when administered twice, is immunogenic for Syrian hamsters and protects them from intranasal infection with 1•105 Plaqueforming units of virulent virus. The vaccine is capable of generating a specific humoral immune response to both the “Delta” variant and the “Omicron” variant of the SARS-CoV-2 virus. Virus neutralizing antibodies for both variants persists in 100 % of animals for 180 days after double immunization. The effect of immunization on cellular immunity is shown.
- 13 March 2026
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 25 (1) , 21-32
Open AccessPreclinical valuation of immunogenicity and effectiveness of inactivated cultural vaccine experimental patterns against coronaviral infection COVID-19
Relevance. Research on the development of new, more advanced vaccines against Covid-19, both based on modern technologies and traditional inactivated ones, remains relevant. In the "48 Central Research Institute" of the Ministry of Defense of the Russian Federation, together with the Yaroslavl Factory of ready-made Dosage Forms of JSC R-Pharm, a cultural (based on Vero (B) cell culture) inactivated with beta-propiolactone chromatographically purified vaccine against coronavirus infection Covid-19 was developed. The aim of the work is to evaluate the results of preclinical studies on its immunogenicity and protective effectiveness in animal experiments. Materials and methods. The immunogenicity and protective activity of experimental vaccine samples with adjuvants aluminum hydroxide and CpG 1018 were evaluated, including in comparison with Sputnik V, after double immunization of Syrian hamsters with an interval of 21 days with intranasal infection with the virulent SARS-CoV-2 virus at a dose of 105 Plaqueforming units/individual. In an experiment on monkeys, the effects of the vaccine on double immunization were evaluated: humoral (virus neutralizing antibodies titer) and cellular immunity indicators for 1 year. Results and discussion. The optimal dose of the vaccine was selected – 15 mcg of protein and the composition of the adjuvants included in it was determined: 500 mcg of aluminum hydroxide and 10 mcg of synthetic oligodeoxynucleotide CpG 1018. The inactivated sorbed vaccine against Covid-19 coronavirus infection, when administered twice with an interval of 21 days, induces the formation of viral neutralizing antibodies in 80-100% of Syrian hamsters at titers of 1:20 or more 21 days after the completion of the immunization cycle and is characterized by a lung protection index ≥ 3.2 lg on the 6th day after infection with 105Plaque-forming units of virulent virus (variant “Delta”). The inactivated sorbed vaccine is capable of generating a humoral immune response in rhesus monkeys to both the “Delta” variant and the “Omicron” variant of the SARS-CoV-2 virus. Virus neutralizing antibodies for both variants persists in 100% of vaccinated animals for 180 days after double immunization. By 42 days after the completion of vaccination, there is an increase in cytotoxic T lymphocytes and a decrease in total B lymphocytes. Conclusions. The inactivated sorbed purified vaccine against Covid-19 coronavirus infection, when administered twice, is immunogenic for Syrian hamsters and protects them from intranasal infection with 1•105 Plaqueforming units of virulent virus. The vaccine is capable of generating a specific humoral immune response to both the “Delta” variant and the “Omicron” variant of the SARS-CoV-2 virus. Virus neutralizing antibodies for both variants persists in 100 % of animals for 180 days after double immunization. The effect of immunization on cellular immunity is shown.
- Open Access
- 19 December 2025
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 25 (4) , 376-388
Protective efficacy of combined monoclonal antibody docaravimab and miromavimab preparation against classical rabies virus: A preclinical study in BALB/c mice
INTRODUCTION . Medicinal products based on monoclonal antibodies (mAbs) is one of the promising options for post-exposure rabies prophylaxis. Since Russian pharmaceutical market does not offer anti-rabies mAbs, a combined docaravimab and miromavimab preparation requires a preclinical study of its protective properties against street strains of the rabies virus circulating in the Russian Federation. In this regard, the need to conduct experimental studies is urgent in order to substantiate the efficacy of such products. AIM . This study aimed to investigate protective efficacy of the combined anti-rabies mAb preparation of docaravimab and miromavimab against the classical rabies virus in BALB/c mice. MATERIALS AND METHODS . A combination of anti-rabies mAbs, docaravimab and miroma-vimab, was used as a test drug, while anti-rabies immunoglobulin Rebinolin served as a comparator drug. Street rabies virus strains were used: 777-M, Russia/Samara/2018, RABV/Russia/SP48SolMak/2020, and fixed CVS strain. In the efficacy study, 960 BALB/c mice (480 females, 480 males) were used, forming 23 groups of 20 animals each (10 males and 10 females). Mice groups 3–18 were intramuscularly infected with the rabies virus, and after 6 or 24 hours, either docaravimab and miromavimab combination or a comparator drug (Rebinolin) was administered intramuscularly. Mice from group 1 and 2 were injected with 0.9% sodium chloride solution (placebo). Mice from groups 19–22 served as a dose control for the virus; group 23 served as an intact control. To assess protective properties, mice were weighed; incubation and clinical period, average life span, and protection from clinical manifestations and death was determined. Virus infectivity was evaluated on BALB/c mice after their intracerebral infection. The specific cause of animal death was confirmed using real-time reverse transcriptase polymerase chain reaction. RESULTS . A combined preparation based on anti-rabies mAbs docaravimab and miromavimab resulted in a significantly increased body weight, average life span, and protection from clinical rabies manifestations in infected mice compared with rabies virus dose control groups. The combined preparation demonstrated high protective efficacy against rabies virus strains, not inferior to that of the comparator. Administration of the combined preparation to mice 6 hours after infection (strains 777-M, Russia/Samara/2018, RABV/Russia/SP48SolMak/2020, CVS) showed 90–100% protection of male and female mice against death; after 24 hours — 90–100% of male and 96–100% of female mice. CONCLUSIONS . An experiment in mice shows high protective efficacy of a combined docaravimab and miromavimab preparation against street strains of the classic rabies virus relevant to the Russian Federation. Protective efficacy of the combined preparation is not inferior to the comparator, thus warranting further preclinical and clinical studies.
- 19 December 2025
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 25 (4) , 376-388
Open AccessProtective efficacy of combined monoclonal antibody docaravimab and miromavimab preparation against classical rabies virus: A preclinical study in BALB/c mice
INTRODUCTION . Medicinal products based on monoclonal antibodies (mAbs) is one of the promising options for post-exposure rabies prophylaxis. Since Russian pharmaceutical market does not offer anti-rabies mAbs, a combined docaravimab and miromavimab preparation requires a preclinical study of its protective properties against street strains of the rabies virus circulating in the Russian Federation. In this regard, the need to conduct experimental studies is urgent in order to substantiate the efficacy of such products. AIM . This study aimed to investigate protective efficacy of the combined anti-rabies mAb preparation of docaravimab and miromavimab against the classical rabies virus in BALB/c mice. MATERIALS AND METHODS . A combination of anti-rabies mAbs, docaravimab and miroma-vimab, was used as a test drug, while anti-rabies immunoglobulin Rebinolin served as a comparator drug. Street rabies virus strains were used: 777-M, Russia/Samara/2018, RABV/Russia/SP48SolMak/2020, and fixed CVS strain. In the efficacy study, 960 BALB/c mice (480 females, 480 males) were used, forming 23 groups of 20 animals each (10 males and 10 females). Mice groups 3–18 were intramuscularly infected with the rabies virus, and after 6 or 24 hours, either docaravimab and miromavimab combination or a comparator drug (Rebinolin) was administered intramuscularly. Mice from group 1 and 2 were injected with 0.9% sodium chloride solution (placebo). Mice from groups 19–22 served as a dose control for the virus; group 23 served as an intact control. To assess protective properties, mice were weighed; incubation and clinical period, average life span, and protection from clinical manifestations and death was determined. Virus infectivity was evaluated on BALB/c mice after their intracerebral infection. The specific cause of animal death was confirmed using real-time reverse transcriptase polymerase chain reaction. RESULTS . A combined preparation based on anti-rabies mAbs docaravimab and miromavimab resulted in a significantly increased body weight, average life span, and protection from clinical rabies manifestations in infected mice compared with rabies virus dose control groups. The combined preparation demonstrated high protective efficacy against rabies virus strains, not inferior to that of the comparator. Administration of the combined preparation to mice 6 hours after infection (strains 777-M, Russia/Samara/2018, RABV/Russia/SP48SolMak/2020, CVS) showed 90–100% protection of male and female mice against death; after 24 hours — 90–100% of male and 96–100% of female mice. CONCLUSIONS . An experiment in mice shows high protective efficacy of a combined docaravimab and miromavimab preparation against street strains of the classic rabies virus relevant to the Russian Federation. Protective efficacy of the combined preparation is not inferior to the comparator, thus warranting further preclinical and clinical studies.
- Open Access
- 12 October 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (5-6) , 11-20
Syrian Golden Hamsters — a Model for Assessing the Efficacy of Antiviral Drugs Against Experimental COVID-9
Introduction. The viral disease COVID-19 has caused a global emergency and attracted the attention of health professionals and the public worldwide. The significant increase in the number of new cases of infection with this virus demonstrates the relevance of finding medications effective against this pathogen. A laboratory model is needed to assess the activity of antiviral drugs. The aim of this study was to develop an experimental model that adequately reproduces the leading syndrome of the human disease COVID-19. Material and methods. Research methods: experimental and analytical. The experiments were conducted using a permanent culture of African green monkey kidney cells — Vero Cl008, as well as Syrian golden hamsters orally infected with various variants of the SARS-CoV-2 virus. Results. A model of the experimental form of COVID-19 in Syrian golden hamsters with oral infection was developed based on a set of parameters (clinical, virological, hematological, and biochemical). It was shown that as a result of oral infection at a dose of 500 ID50 animals developed lung damage, a decrease in the number of leukocytes in the blood, an increase in the proportion of young and band forms of neutrophils with a simultaneous decrease in the proportion of segmented neutrophils, lymphocytes, an increase in the activity of aspartate and alanine aminotransferases (AST and ALT), an increase in the concentration of urea, creatinine, lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) in the blood serum. The following indicators were used to calculate the disease severity index and the therapeutic effect factor: virus accumulation in the lungs, the degree of lung damage (pathological changes), the levels of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, creatinine kinase, urea, creatinine, the relative number of myelocytes, young, band, segmented neutrophils, and lymphocytes. Conclusion. The proposed model of the experimental form of COVID-19 in Syrian golden hamsters adequately reproduces the leading syndrome of the disease (viral pneumonia) and allows for a more objective assessment of the effectiveness of antiviral drugs with the calculation of the disease severity index and the therapeutic effect coefficient.
- 12 October 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (5-6) , 11-20
Open AccessSyrian Golden Hamsters — a Model for Assessing the Efficacy of Antiviral Drugs Against Experimental COVID-9
Introduction. The viral disease COVID-19 has caused a global emergency and attracted the attention of health professionals and the public worldwide. The significant increase in the number of new cases of infection with this virus demonstrates the relevance of finding medications effective against this pathogen. A laboratory model is needed to assess the activity of antiviral drugs. The aim of this study was to develop an experimental model that adequately reproduces the leading syndrome of the human disease COVID-19. Material and methods. Research methods: experimental and analytical. The experiments were conducted using a permanent culture of African green monkey kidney cells — Vero Cl008, as well as Syrian golden hamsters orally infected with various variants of the SARS-CoV-2 virus. Results. A model of the experimental form of COVID-19 in Syrian golden hamsters with oral infection was developed based on a set of parameters (clinical, virological, hematological, and biochemical). It was shown that as a result of oral infection at a dose of 500 ID50 animals developed lung damage, a decrease in the number of leukocytes in the blood, an increase in the proportion of young and band forms of neutrophils with a simultaneous decrease in the proportion of segmented neutrophils, lymphocytes, an increase in the activity of aspartate and alanine aminotransferases (AST and ALT), an increase in the concentration of urea, creatinine, lactate dehydrogenase (LDH), and creatine phosphokinase (CPK) in the blood serum. The following indicators were used to calculate the disease severity index and the therapeutic effect factor: virus accumulation in the lungs, the degree of lung damage (pathological changes), the levels of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, creatinine kinase, urea, creatinine, the relative number of myelocytes, young, band, segmented neutrophils, and lymphocytes. Conclusion. The proposed model of the experimental form of COVID-19 in Syrian golden hamsters adequately reproduces the leading syndrome of the disease (viral pneumonia) and allows for a more objective assessment of the effectiveness of antiviral drugs with the calculation of the disease severity index and the therapeutic effect coefficient.
- Open Access
- 6 August 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (3-4) , 69-83
Promising Directions for the Development of Chemotherapy for Viral Infections
Viral infections occupy a leading place in various human pathologies and are one of the main causes of death among people, both in developed and developing countries with a weak health care system. The huge diversity of viruses and their unique variability pose a serious challenge to the developers of antiviral agents. The purpose of this review is to analyze the current state of development of emergency prevention and treatment agents, as well as promising areas for the development of chemotherapy for viral infections. The main direction in the development of effective means for the treatment of viral infections is the creation of medications based on abnormal nucleosides and their precursors, small interfering RNA, releaseactive compounds, and the search for targets among viral proteins. The review considers the most significant results in the field of creating agents for the treatment of viral infections.
- 6 August 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (3-4) , 69-83
Open AccessPromising Directions for the Development of Chemotherapy for Viral Infections
Viral infections occupy a leading place in various human pathologies and are one of the main causes of death among people, both in developed and developing countries with a weak health care system. The huge diversity of viruses and their unique variability pose a serious challenge to the developers of antiviral agents. The purpose of this review is to analyze the current state of development of emergency prevention and treatment agents, as well as promising areas for the development of chemotherapy for viral infections. The main direction in the development of effective means for the treatment of viral infections is the creation of medications based on abnormal nucleosides and their precursors, small interfering RNA, releaseactive compounds, and the search for targets among viral proteins. The review considers the most significant results in the field of creating agents for the treatment of viral infections.
- Open Access
- 19 April 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (11-12) , 49-58
Antiviral Activity of 5-chloropyridin-3-yl-1h-indole-4-carboxylate (AMND) Against COVID-19
Introduction. The viral disease COVID-19 has caused a global emergency. The rapid and widespread spread of COVID-19 and the urgent need for etiotropic drugs have sparked interest in repositioning existing drugs. SARS-CoV proteases (Mpro) and papain protease (PLpro) have been identified as attractive targets for the development of antiviral agents.The aim of this work was to evaluate the antiviral efficacy of indole chloropyridinyl ethers against the SARS-CoV-2 virus in vitro, as well as against the experimental form of COVID-19 in Syrian golden hamsters.Material and methods. The experiments were carried out on a permanent culture of African green monkey kidney cells — Vero Cl008. The effectiveness of the drugs was assessed by suppressing the reproduction of the virus in vitro. Biological activity was assessed by titration of the viruscontaining suspension in Vero Cl008 cell culture by the formation of negative colonies. Syrian golden hamsters orally infected with the SARS-CoV-2 virus, variant B, were used. The effectiveness of the drug was assessed by the coefficient of therapeutic action.Results. The antiviral efficacy of indole chloropyridinyl ethers against the new pandemic virus SARSCoV-2 was studied in vitro during experiments in Vero C1008 cell culture. The results of the study revealed that the drugs effectively suppress the reproduction of the virus when applied after infection. In the concentration range of 12.5–50.0 µg/ml, the drugs almost completely suppress the reproduction of the SARS-CoV-2 virus. According to the complex of clinical, virological, biochemical, and hematological indicators, the disease severity indех (DSI) and the therapeutic action coefficient (TAC) were calculated. For AMND-1X — the DSI was 0.635; the TAC was 36.5%; for AMND-1OL-3 — the DSI was 0.115; the TAC was 88.5%. Conclusion. Of the studied compounds, the drug AMND-1OL-3 showed the highest antiviral activity.
- 19 April 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (11-12) , 49-58
Open AccessAntiviral Activity of 5-chloropyridin-3-yl-1h-indole-4-carboxylate (AMND) Against COVID-19
Introduction. The viral disease COVID-19 has caused a global emergency. The rapid and widespread spread of COVID-19 and the urgent need for etiotropic drugs have sparked interest in repositioning existing drugs. SARS-CoV proteases (Mpro) and papain protease (PLpro) have been identified as attractive targets for the development of antiviral agents.The aim of this work was to evaluate the antiviral efficacy of indole chloropyridinyl ethers against the SARS-CoV-2 virus in vitro, as well as against the experimental form of COVID-19 in Syrian golden hamsters.Material and methods. The experiments were carried out on a permanent culture of African green monkey kidney cells — Vero Cl008. The effectiveness of the drugs was assessed by suppressing the reproduction of the virus in vitro. Biological activity was assessed by titration of the viruscontaining suspension in Vero Cl008 cell culture by the formation of negative colonies. Syrian golden hamsters orally infected with the SARS-CoV-2 virus, variant B, were used. The effectiveness of the drug was assessed by the coefficient of therapeutic action.Results. The antiviral efficacy of indole chloropyridinyl ethers against the new pandemic virus SARSCoV-2 was studied in vitro during experiments in Vero C1008 cell culture. The results of the study revealed that the drugs effectively suppress the reproduction of the virus when applied after infection. In the concentration range of 12.5–50.0 µg/ml, the drugs almost completely suppress the reproduction of the SARS-CoV-2 virus. According to the complex of clinical, virological, biochemical, and hematological indicators, the disease severity indех (DSI) and the therapeutic action coefficient (TAC) were calculated. For AMND-1X — the DSI was 0.635; the TAC was 36.5%; for AMND-1OL-3 — the DSI was 0.115; the TAC was 88.5%. Conclusion. Of the studied compounds, the drug AMND-1OL-3 showed the highest antiviral activity.
- Open Access
- 21 June 2024
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (3-4) , 21-30
Comparative Analysis of the Antiviral Activity of Various Drugs Based on 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide (Favipiravir) Against COVID-19
Background. The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, originated in Wuhan, China, has claimed millions of lives around the world. In this regard, the search for effective drugs, including the repurposing of existing ones, has become an urgent task. A promising treatment strategy appears to be drug disruption of viral reproduction. RNA-dependent RNA polymerase (RdRp) is the central subunit of the RNA synthesis process for all positive-strand RNA viruses and is therefore an attractive target for antiviral inhibitors.The aim of this work is an experimental study of the antiviral activity of various drugs based on 6-fluoro-3-hydroxy-2-pyrazinecarboxamide (Favipiravir) in vitro and in vivo against the SARS-CoV-2 coronavirus (COVID-19).Material and methods. The experiments were carried out on a permanent culture of African green monkey kidney cells — Vero Cl008. The effectiveness of the drugs was assessed by suppressing the reproduction of the virus in vitro. Biological activity was assessed by titration of the virus-containing suspension in Vero Cl008 cell culture by the formation of negative colonies. Syrian golden hamsters orally infected with the SARS-CoV-2 virus, variant B, were used in the study. The effectiveness of the drug was assessed by the coefficient of therapeutic action.Results. The results of the study revealed that the compounds FP-1 and Avifavir in the concentration range of 100–400 µg/ml almost completely suppress the reproduction of the SARS-CoV-2 virus; the CTI index for the drug FP-1 was 4, for Avifavir it was 2. The ED₅₀ value for FP-1 was 26 µg/ml, for Avifavir it was 36 µg/ml. Preparations T-705 and Coronavir revealed antiviral activity only at extremely high concentrations. The CTI was 1. During the study on Syrian golden hamsters orally infected with the SARS-CoV-2 virus, variant B, at a dose of 5×105 PFU, it was shown that the use of Avifavir and FP-1 has a high protective efficacy, while Coronavir and T-705 cause a moderate suppression of virus reproduction in the target organ. According to the complex of clinical-virological, biochemical, and hematological indicators, the disease severity index (DSI) and the therapeutic index (TI) were calculated. For the drug Avifavir, the DSI was 0.269; the TI was 71.3% with a probability of 99.9%.Conclusion. Of the studied compounds, Avifavir and FP-1 showed the highest antiviral activity.
- 21 June 2024
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (3-4) , 21-30
Open AccessComparative Analysis of the Antiviral Activity of Various Drugs Based on 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide (Favipiravir) Against COVID-19
Background. The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, originated in Wuhan, China, has claimed millions of lives around the world. In this regard, the search for effective drugs, including the repurposing of existing ones, has become an urgent task. A promising treatment strategy appears to be drug disruption of viral reproduction. RNA-dependent RNA polymerase (RdRp) is the central subunit of the RNA synthesis process for all positive-strand RNA viruses and is therefore an attractive target for antiviral inhibitors.The aim of this work is an experimental study of the antiviral activity of various drugs based on 6-fluoro-3-hydroxy-2-pyrazinecarboxamide (Favipiravir) in vitro and in vivo against the SARS-CoV-2 coronavirus (COVID-19).Material and methods. The experiments were carried out on a permanent culture of African green monkey kidney cells — Vero Cl008. The effectiveness of the drugs was assessed by suppressing the reproduction of the virus in vitro. Biological activity was assessed by titration of the virus-containing suspension in Vero Cl008 cell culture by the formation of negative colonies. Syrian golden hamsters orally infected with the SARS-CoV-2 virus, variant B, were used in the study. The effectiveness of the drug was assessed by the coefficient of therapeutic action.Results. The results of the study revealed that the compounds FP-1 and Avifavir in the concentration range of 100–400 µg/ml almost completely suppress the reproduction of the SARS-CoV-2 virus; the CTI index for the drug FP-1 was 4, for Avifavir it was 2. The ED₅₀ value for FP-1 was 26 µg/ml, for Avifavir it was 36 µg/ml. Preparations T-705 and Coronavir revealed antiviral activity only at extremely high concentrations. The CTI was 1. During the study on Syrian golden hamsters orally infected with the SARS-CoV-2 virus, variant B, at a dose of 5×105 PFU, it was shown that the use of Avifavir and FP-1 has a high protective efficacy, while Coronavir and T-705 cause a moderate suppression of virus reproduction in the target organ. According to the complex of clinical-virological, biochemical, and hematological indicators, the disease severity index (DSI) and the therapeutic index (TI) were calculated. For the drug Avifavir, the DSI was 0.269; the TI was 71.3% with a probability of 99.9%.Conclusion. Of the studied compounds, Avifavir and FP-1 showed the highest antiviral activity.
- Open Access
- 29 October 2022
- Published by Russian Research Anti-Plague Institute Microbe in Problems of Particularly Dangerous Infections
- No. 3,p. 53-60
The Flow Cytometry Study of Cellular Immunity in Rhesus Monkeys after Experimental Infection with SARS CoV 2 Virus
Cellular immunity plays an important role in the pathogenesis and formation of protective immune defense against the SARS‑CoV‑2 virus.The aim of the work was to study the cellular immunity of rhesus monkeys applying flow cytometry after experimental infection with the SARS‑CoV‑2 virus.Materials and methods. Male rhesus monkeys were intranasally inoculated with the SARS‑CoV‑2 virus, Isolate B strain and hCoV-19/Russia/SP48-1226/2020 strain (abbreviated name U-2), at a dose of 5.0 lg PFU. Using flow cytometry, the levels of 21 populations/subpopulations of mononuclear cells in the peripheral blood of animals were determined before experimental infection with the pathogen and on day 14 after infection. SARS‑CoV‑2 coronavirus RNA was assessed using real-time polymerase chain reaction. Determination of the titer of virus-neutralizing antibodies to the SARS‑CoV‑2 virus in the blood sera of animals was conducted through neutralization test evaluating the ability to suppress negative colonies.Results and discussion. Infection with Isolate B strain culture has led to an increase in the relative content of total T-lymphocytes (p˂0.2), cytotoxic T-lymphocytes (p˂0.1), as well as monocytes expressing the early activation marker CD25 (p˂0.2). The decrease in levels has been observed for total B-lymphocytes (p˂0.2) and T-helper cells (p˂0.1). Infection with the U-2 strain culture revealed an increase in the relative content of monocytes expressing the early activation marker CD25 (p˂0.2). Thus, for the first time in the Russian Federation, flow cytometry was used to study the cellular immunity of rhesus monkeys before and after experimental infection with the SARS‑CoV‑2 virus. The obtained information can be used for studying the pathogenesis of SARS‑CoV‑2 infection, course, and outcome of the disease, and developing strategies for vaccination and treatment.
- 29 October 2022
- Published by Russian Research Anti-Plague Institute Microbe in Problems of Particularly Dangerous Infections
- No. 3,p. 53-60
Open AccessThe Flow Cytometry Study of Cellular Immunity in Rhesus Monkeys after Experimental Infection with SARS CoV 2 Virus
Cellular immunity plays an important role in the pathogenesis and formation of protective immune defense against the SARS‑CoV‑2 virus.The aim of the work was to study the cellular immunity of rhesus monkeys applying flow cytometry after experimental infection with the SARS‑CoV‑2 virus.Materials and methods. Male rhesus monkeys were intranasally inoculated with the SARS‑CoV‑2 virus, Isolate B strain and hCoV-19/Russia/SP48-1226/2020 strain (abbreviated name U-2), at a dose of 5.0 lg PFU. Using flow cytometry, the levels of 21 populations/subpopulations of mononuclear cells in the peripheral blood of animals were determined before experimental infection with the pathogen and on day 14 after infection. SARS‑CoV‑2 coronavirus RNA was assessed using real-time polymerase chain reaction. Determination of the titer of virus-neutralizing antibodies to the SARS‑CoV‑2 virus in the blood sera of animals was conducted through neutralization test evaluating the ability to suppress negative colonies.Results and discussion. Infection with Isolate B strain culture has led to an increase in the relative content of total T-lymphocytes (p˂0.2), cytotoxic T-lymphocytes (p˂0.1), as well as monocytes expressing the early activation marker CD25 (p˂0.2). The decrease in levels has been observed for total B-lymphocytes (p˂0.2) and T-helper cells (p˂0.1). Infection with the U-2 strain culture revealed an increase in the relative content of monocytes expressing the early activation marker CD25 (p˂0.2). Thus, for the first time in the Russian Federation, flow cytometry was used to study the cellular immunity of rhesus monkeys before and after experimental infection with the SARS‑CoV‑2 virus. The obtained information can be used for studying the pathogenesis of SARS‑CoV‑2 infection, course, and outcome of the disease, and developing strategies for vaccination and treatment.
- Open Access
- 21 July 2021
- Published by Russian Research Anti-Plague Institute Microbe in Problems of Particularly Dangerous Infections
- No. 2,p. 6-15
Laboratory Diagnosis of Rabies. Current State and Trends in Development
The review considers the relevant aspects of laboratory diagnosis of rabies. The methods of laboratory diagnostics of rabies infection, standardized by WHO in 2018, and their use in the Russian Federation are presented. The scheme of laboratory diagnostics of rabies, applied by specialists of the “48th CRI” of the Ministry of Defense of Russia, for the study of biological samples from deceased people is outlined. Between 2002 and 2018, the study of biomaterial was carried out using molecular-biological, virological methods of diagnosis and in some cases electron microscopy, which allowed to detect and identify the pathogen in 257 samples from 71 people, to certify and deposit new isolates of the rabies virus. Accumulation and analysis of the lessons learned in the application of molecular-biological method of rabies diagnosis allows us to recommend the use of RT-PCR, real-time RT-PCR sets (having a certificate of state registration) in healthcare and veterinary medicine practice to identify the causative agent of rabies infection. The use of molecular-biological methods is promising in terms of the development of rabies diagnosis to improve epidemiological surveillance and raise the efficiency of the biological protection of the population of the Russian Federation.
- 21 July 2021
- Published by Russian Research Anti-Plague Institute Microbe in Problems of Particularly Dangerous Infections
- No. 2,p. 6-15
Open AccessLaboratory Diagnosis of Rabies. Current State and Trends in Development
The review considers the relevant aspects of laboratory diagnosis of rabies. The methods of laboratory diagnostics of rabies infection, standardized by WHO in 2018, and their use in the Russian Federation are presented. The scheme of laboratory diagnostics of rabies, applied by specialists of the “48th CRI” of the Ministry of Defense of Russia, for the study of biological samples from deceased people is outlined. Between 2002 and 2018, the study of biomaterial was carried out using molecular-biological, virological methods of diagnosis and in some cases electron microscopy, which allowed to detect and identify the pathogen in 257 samples from 71 people, to certify and deposit new isolates of the rabies virus. Accumulation and analysis of the lessons learned in the application of molecular-biological method of rabies diagnosis allows us to recommend the use of RT-PCR, real-time RT-PCR sets (having a certificate of state registration) in healthcare and veterinary medicine practice to identify the causative agent of rabies infection. The use of molecular-biological methods is promising in terms of the development of rabies diagnosis to improve epidemiological surveillance and raise the efficiency of the biological protection of the population of the Russian Federation.